PT0101 / Periotherapia - LARVOL DELTA

PT0101-CT1: A phase I/IIa, first-in-human, open-label, multicenter trial of anti-periostin antibody (PT0101) in patients with advanced solid cancers and HER2-negative recurrent or metastatic breast cancer (ESMO 2025) - P | "Part 2 is evaluating the safety of PT0101 in combination with paclitaxel (PTX; 80 mg/m 2 ). Phase I of PT0101-CT1 started in Feb. 2025 and is ongoing."

Clinical • First-in-human • Metastases • P1/2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • POSTN